The company has a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a “do not eat” signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. By blocking this “do not eat” signal with decoy receptors, we aim to unmask tumor cells and make them visible to the immune system. Within this program Trillium has two decoy receptors (TTI-621 and TTI-622) that are currently being evaluated in patients with hematologic and solid tumors. The company also has a growing pipeline of discovery stage programs targeting other pathways in immuno-oncology, including a small molecule STING agonist.
Prior to going public in 2013, Trillium was a company of 12 employees. We have continued to evolve to meet the ever changing demand for newer and better cancer therapeutics. Located near Toronto, Ontario and named after the province’s official flower, Trillium grandiflorum, Trillium is home to a globally diverse group of people dedicated to improving the lives of cancer patients.